MLICM
VRCA icon

Metropolitan Life Insurance Company (MetLife)’s Verrica Pharmaceuticals VRCA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-116
Closed -$6.69K – 2451
2023
Q2 		$6.69K Buy
+116
New +$7.04K ﹤0.01% 2437

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VRCA Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Verrica Pharmaceuticals (VRCA) in Q3 2023, closing a stake of 116 shares — an estimated $6.69K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VRCA in Q2 2023 and held it in 1 quarter. The position peaked at $6.69K in Q2 2023. 67 funds tracked by Wall St. Rank hold VRCA as of Q3 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Verrica Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 116 Verrica Pharmaceuticals shares in Q3 2023, an estimated $6.69K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Verrica Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Verrica Pharmaceuticals position peaked at $6.69K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.